Co-Diagnostics Inc CODX

$1.08 0.00 (—)

Valuation

Market cap
7,540,000
Revenue TTM
$620,000
Net income TTM
$-46,900,000
PE ratio
0.00
Forward PE
—
Profit margin
-7,564.52%
Debt to equity
0.00

Trading

Volume
83,400
Avg volume
343,930
Day's range
$1.06 – $1.10
Shares out
6,981,000
Stochastic %K
50%
Beta
2.90
Analysts
Sell
Price target
$4.00

Price

Company profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic test...

Show more

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Industry
Medical Devices
Sector
Healthcare
Phone
801 438 1036
Website
https://co-dx.com
Address
2401 S. Foothill Drive, Suite D, Salt Lake City, United States

Latest news

No headlines yet.

Stocktwits

thatsolardude365 Oct 3, 12:56 PM
$CODX investors: an open class action alleges Co-Diagnostics hid collapsing demand for its Logix Smart COVID test. $6.5M settlement, about $0.36 a share before fees. Claims close Jan 6. Open Class Actions.
0 replies
Antiquarian Oct 2, 1:53 PM
$CODX Day 132 one day chart still frozen. Stocktwits support says they don’t see an issue. I can view it from other apps but this is annoying. The drop in price is annoying as well
1 replies
CoffeeRocks Oct 2, 11:48 AM 0 replies
Millones Oct 1, 6:12 PM
$CODX Announcement coming soon regarding update/unveiling of the new CoMira facility. It will coincide with the one year anniversary and the upcoming biotech conference in Dubai. As similar to other announcements, it will likely be the precursor to the dilution event. Be on the lookout. Additionally, expecting an after hours SEC filing detailing the shareholder meeting. It doesn’t appear the company has met quorum, again, which would be an unprecedented third time failure. Although if measures were passed, and reduced quorum amendment accepted by shareholders, the reverse split and dilution special meeting will come quickly. But since it hasn’t been announced yet, I’m leaning towards another lack of quorum filing. Keep an eye on this over the coming weeks. Company is likely on their last couple of dollars for maintaining operations, so a Hail Mary may be coming. As always, NFA and DYOR. Best of luck 🧬🧮🕰️™️
3 replies
LuckyEnzo Oct 1, 8:48 AM
@EquivalentExchange is on an absolute tear recently🔥the plays just keep getting better! If you’re not following yet you’re missing out. $BATL $CODX $CLDI next!
0 replies
diamondhope Sep 30, 7:36 PM
$CODX Solvency Issue,,,,lol What solvent can dissolve slime?
1 replies
SmallPhish Sep 30, 2:41 PM
$CODX When is the next road trip for the Egan clan?
0 replies
SmallPhish Sep 30, 2:39 PM
$CODX 1.08/30/30=0.0012 will be the real share price if another reverse split is authorized
0 replies